Raptor Pharmaceuticals Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

April 2024 | 50 pages | ID: R1C2E8BDD90BEN
BAC Reports

Abstracts

Raptor Pharmaceuticals Corp. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Raptor Pharmaceuticals Corp. and its competitors. This provides our Clients with a clear understanding of Raptor Pharmaceuticals Corp. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Raptor Pharmaceuticals Corp. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Raptor Pharmaceuticals Corp.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Raptor Pharmaceuticals Corp. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Raptor Pharmaceuticals Corp. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Raptor Pharmaceuticals Corp. business.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company’s product portfolio includes both candidates from its proprietary drug targeting platforms and in-licensed and acquired product candidates.

Product Pipeline

The company’s pipeline includes three clinical development programs. It also has three other clinical-stage product candidates and four preclinical product candidates.

Clinical Development Programs

The company’s three active clinical development programs are based on a therapeutic that it is reformulating for improvement for application in new disease indications. These clinical development programs include the following: DR Cysteamine for the treatment of nephropathic cystinosis (cystinosis), a genetic disorder; DR Cysteamine for the treatment of non-alcoholic steatohepatitis (NASH), a metabolic disorder of the liver; and DR Cysteamine for the treatment of Huntington’s Disease (HAD).

Other Clinical-Stage Product Candidates

The company has three clinical-stage product candidates for which it is seeking partners: Convivia for the management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase (ALDH2) deficiency, an inherited metabolic disorder; and Tezampanel and NGX426, non-opioids for the treatment of migraine, acute pain, and chronic pain.

Preclinical Product Candidates

The company’s preclinical platforms consist of targeted therapeutics for the treatment of multiple indications, including liver diseases, neurodegenerative diseases, and breast cancer. Its preclinical platforms include the following:

The company’s receptor-associated protein (RAP) platform consists of: HepTide for the treatment of primary liver cancer and other liver diseases; and NeuroTrans to deliver therapeutics across the blood-brain barrier for treatment of various neurological diseases.

The company’s mesoderm development protein (Mesd) platform consists of WntTide for the treatment of breast cancer. It is also examining its glutamate receptor antagonists, tezampanel, and NGX426 for the treatment of thrombosis disorder.

History

Raptor Pharmaceuticals Corp. was founded in 2005.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. RAPTOR PHARMACEUTICALS CORP. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. RAPTOR PHARMACEUTICALS CORP. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. RAPTOR PHARMACEUTICALS CORP. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. RAPTOR PHARMACEUTICALS CORP. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. RAPTOR PHARMACEUTICALS CORP. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Raptor Pharmaceuticals Corp. Direct Competitors
5.2. Comparison of Raptor Pharmaceuticals Corp. and Direct Competitors Financial Ratios
5.3. Comparison of Raptor Pharmaceuticals Corp. and Direct Competitors Stock Charts
5.4. Raptor Pharmaceuticals Corp. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Raptor Pharmaceuticals Corp. Industry Position Analysis

6. RAPTOR PHARMACEUTICALS CORP. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. RAPTOR PHARMACEUTICALS CORP. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. RAPTOR PHARMACEUTICALS CORP. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. RAPTOR PHARMACEUTICALS CORP. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. RAPTOR PHARMACEUTICALS CORP. PORTER FIVE FORCES ANALYSIS²

12. RAPTOR PHARMACEUTICALS CORP. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Raptor Pharmaceuticals Corp. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Raptor Pharmaceuticals Corp. 1-year Stock Charts
Raptor Pharmaceuticals Corp. 5-year Stock Charts
Raptor Pharmaceuticals Corp. vs. Main Indexes 1-year Stock Chart
Raptor Pharmaceuticals Corp. vs. Direct Competitors 1-year Stock Charts
Raptor Pharmaceuticals Corp. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Raptor Pharmaceuticals Corp. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Raptor Pharmaceuticals Corp. Key Executives
Raptor Pharmaceuticals Corp. Major Shareholders
Raptor Pharmaceuticals Corp. History
Raptor Pharmaceuticals Corp. Products
Revenues by Segment
Revenues by Region
Raptor Pharmaceuticals Corp. Offices and Representations
Raptor Pharmaceuticals Corp. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Raptor Pharmaceuticals Corp. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Raptor Pharmaceuticals Corp. Capital Market Snapshot
Raptor Pharmaceuticals Corp. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Raptor Pharmaceuticals Corp. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Raptor Pharmaceuticals Corp. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?